Takeda Pharmaceutical Company Ltd. (TSE:4502/NYSE:TAK) is moving forward with its plan to acquire its collaborator GammaDelta Therapeutics Ltd. (London).
The acquisition is subject to customary closing conditions. Takeda projects that the deal will close in the first quarter of its fiscal year, which will end on June 30, 2022.
The acquisition would bolster Takeda’s immuno-oncology and immunotherapy portfolio, given GammaDelta’s experience working with gamma delta (γδ) T cells as potential therapies for solid tumors hematological malignancies.
GammaDelta had developed allogeneic variable delta 1 (Vδ1) gamma-delta (γδ) T cell therapy platforms. Those platforms encompass blood-derived and tissue-derived cells.
“We’re committed to developing cell therapies that will have an impact on large segments of patients by focusing on off-the-shelf, allogeneic cell therapies that are highly accessible and have the potential to address solid tumors,” Christopher…